Upcoming Seminars, Events & Industry Trade Shows

Coffee, Continental Breakfast
Introductions and Welcome

Introducing electron diffraction, a dedicated electron diffractometer, and the benefits for the Pharma industry

Electron diffraction (3D ED, also known as microED) has emerged as a powerful technique for structural analysis on particles smaller than 1000 nm, offering unique advantages in studying crystalline materials. This presentation introduces the fundamental principles of electron diffraction and highlights the capabilities of the ELDICO ED-1, a state-of-the-art electron diffractometer designed specifically for sub-microcrystalline samples.

The ELDICO ED-1, engineered with Swiss precision and innovation, features a unique, optimized design that is tailored for the structure elucidation of nano-sized particles, ensuring the highest quality results. With utmost flexibility in mind, the ELDICO ED-1 has a cutting-edge goniometer, zero distortion by objective lenses, fixed sample-to-detector distance, and advanced automation capabilities. This not only enhances performance but also ensures that the system is ready for the future of electron diffraction as it opens new applications like the so-called Electron Diffraction Crystal Mapping, which can help, for instance, to identify unknown new phases or micro crystallinity in amorphous samples. Other applications interesting for people working in the pharmaceutical industry in the areas of drug discovery, solid state research, chemistry, process development, formulation and IP regulations will also be addressed.

Case studies: Using a dedicated electron diffractometer for pharmaceutical applications

The application of electron diffraction in the pharmaceutical industry is rapidly transforming how researchers analyze and characterize microcrystalline materials. This presentation delves into real-world case studies demonstrating the use of a dedicated electron diffractometer, the ELDICO ED-1, in pharmaceutical research and development. The case studies illustrate how electron diffraction can assist even when traditional methods fall short. Some example case studies which will be presented are:

- accurately identify polymorphs, cocrystals, or salts
- determine the absolute configuration of a molecule
- detect unknown impurities in a formulation
- crystallization and molecular structure using very low amounts of sample (< 100 µg)

By showcasing successful implementations of the ELDICO ED-1 in overcoming specific challenges in drug development, this talk highlights the instrument's impact on accelerating innovation, improving efficiency, and ensuring the reliability of pharmaceutical processes. Attendees will gain practical insights into the advantages of incorporating electron diffraction into their workflows, positioning them at the forefront of cutting-edge pharmaceutical research

Break

Three Things You Need to Know About Protecting Your Pharmaceutical Intellectual Property

In pharmaceutical R&D, we are constantly pressured to develop a solid form of a drug that is reproducible, stable, and has optimal particle size distribution. In addition, process chemists are challenged to create a process to manufacture the desired solid form in a high yield and with sufficient target purity. To succeed in such endeavors, “inventing the wheel” is sometimes required, involving nontraditional multi-disciplinary efforts. However, protecting the invention requires more than just handing laboratory records to patent attorneys.
Pharmaceutical patents can face several hurdles that can invalidate claims, with one of them being the aptly named “death squads”, intent on killing IP rights.
In this presentation, we will discuss three things chemists need to know to protect intellectual property. we will also discuss several crystalline form and process patent examples to learn from the failures and successes of other patent applications.

Rapid Screening and Development of Amorphous Solid Dispersions (ASD)

Amorphous solid dispersions (ASD) have long been used to increase the solubility and bioavailability of poorly soluble compounds. A considerable amount of research has been carried out and knowledge of the amorphous state and ASD has significantly advanced over the last decade. Surprisingly, the number of examples that combine the different stages of ASD development has been meager. Herein, case studies are presented where ASD candidates were rapidly determined within 2-3 weeks by utilizing a compilation of these techniques. Examples of crystallization onset detection with various analytical techniques, including microED will be presented.

Lunch, Networking & Discussions